Test­ing Pro­gram Fails Sol­diers, Leav­ing Brain Injuries Unde­tected (ProPublica):

“In 2007, with road­side bombs explod­ing across Iraq, Con­gress moved to improve care for sol­diers who had suf­fered one of the war’s sig­na­ture wounds, trau­matic brain injury.

Law­mak­ers passed a mea­sure requir­ing the mil­i­tary to test sol­diers’ brain func­tion before they deployed and again when they returned. The test was sup­posed to ensure that sol­diers received proper treatment.

Instead, an inves­ti­ga­tion by ProP­ub­lica and NPR has found, the test­ing pro­gram has failed to deliver on its promise, offer­ing sol­diers the appear­ance of help, but not the real­ity. Read the rest of this entry »

Front Porch Cen­ter for Tech­nol­ogy Inno­va­tion and Well­be­ing Receives Grant for the Model eHealth Com­mu­nity for Aging (press release):

- ” The Front Porch Cen­ter for Tech­nol­ogy Inno­va­tion and Well­be­ing (Front Porch Cen­ter), a 501©(3) founded on the belief that tech­nol­ogy inno­va­tion plays a vital role in enhanc­ing well­be­ing, was awarded eHealth equip­ment val­ued at approx­i­mately $207,000 through the Model eHealth Com­mu­ni­ties ini­tia­tive at UC Davis Health Sys­tem and the Read the rest of this entry »

(Editor’s note: Path­ways respon­si­ble for higher-order think­ing in the pre­frontal cor­tex (PFC), or exec­u­tive cen­ter of the brain, remain vul­ner­a­ble through­out life—during crit­i­cal early-life devel­op­men­tal win­dows, when the PFC fully matures in the early 20s, and finally from declines asso­ci­ated with old age. At all ages, phys­i­cal activ­ity and PFC-navigated social con­nec­tions are essen­tial com­po­nents to main­tain­ing brain health. The Expe­ri­ence Corps, a community-based social-engagement pro­gram, part­ners seniors with local schools to pro­mote purpose-driven involve­ment. Par­tic­i­pat­ing seniors have exhib­ited imme­di­ate short-term gains in brain regions vul­ner­a­ble to aging, such as the PFC, indi­cat­ing that peo­ple with the most to lose have the most to gain from envi­ron­men­tal enrichment.)

Over the last decade, sci­en­tists made two key dis­cov­er­ies that reframed our under­stand­ing of the adult brain’s poten­tial to ben­e­fit from life­long envi­ron­men­tal enrich­ment. First, they learned that the adult brain remains plas­tic; it can gen­er­ate new neu­rons in response to phys­i­cal activ­ity and new expe­ri­ences. Sec­ond, they con­firmed the impor­tance of social con­nect­ed­ness to late-life cog­ni­tive, psy­cho­log­i­cal, and phys­i­cal health. The inte­gra­tion of these find­ings with our under­stand­ing of indi­vid­u­als’ devel­op­men­tal needs through­out life under­scores the impor­tance of the “social brain.” The pre­frontal cor­tex (PFC) is par­tic­u­larly inte­gral to nav­i­gat­ing com­plex social behav­iors and hier­ar­chies over the life course. Read the rest of this entry »

Dr. John Docherty is an Adjunct Pro­fes­sor of Psy­chi­a­try at the Weill Med­ical Col­lege, Cor­nell Uni­ver­sity, Direc­tor of Post Grad­u­ate Edu­ca­tion there, and Chief Med­ical Offi­cer of Brain Resource. Trained as a clin­i­cal research fel­low in neu­ropsy­chophar­ma­col­ogy at NIMH, he later returned as Chief of the Psy­choso­cial Treat­ments Research Branch, respon­si­ble for all fed­er­ally sup­ported psy­choso­cial treat­ment research in men­tal health nation­wide. He over­saw the land­mark National Col­lab­o­ra­tive Study of the Treat­ment of Depres­sion and served as a mem­ber and Chair­man for over 10 years on the NIMH and then NIDA Treat­ment Research IRGs. Dr. Docherty has wide expe­ri­ence in suc­cess­fully imple­ment­ing inno­va­tion in both clin­i­cal oper­a­tions and man­aged health care. He founded North­east Psy­chi­atric Asso­ciates in 1985. As National Med­ical Direc­tor for National Med­ical Enter­prises, he over­saw med­ical con­trol and qual­ity improve­ment in 74 hos­pi­tals in 34 states. He was the Exec­u­tive Vice-President and Chief Med­ical Offi­cer for Merit Behav­ioral Care, which then cov­ered 30 mil­lion peo­ple. In 1998, he founded Com­pre­hen­sive Neu­ro­Science (CNS). Its Care Man­age­ment Tech­nolo­gies are cur­rently imple­mented in 17 state Med­ic­aid plans. Dr Docherty has received numer­ous hon­ors and awards and has authored over 100 sci­en­tific publications.

(Editor’s note: this inter­view with Dr. John Docherty was orig­i­nally pub­lished in Sharp­Brains’ mar­ket report Trans­form­ing Brain Health with Dig­i­tal Tools to Assess, Enhance and Treat Cog­ni­tion across the Lifes­pan, pub­lished in July 2010)

Alvaro Fer­nan­dez: Dr. Docherty, it is a plea­sure to be with you today to dis­cuss the main theme of Sharp­Brains’ 2010 mar­ket report – how the con­ver­gence of sci­en­tific find­ings and tech­nol­ogy plat­forms and tools is reshap­ing how as a soci­ety and as indi­vid­u­als we will take care of cog­ni­tion and men­tal well­ness along the life­course, giv­ing birth to the emerg­ing dig­i­tal brain health and fit­ness mar­ket. Can you first briefly dis­cuss your career tra­jec­tory and your cur­rent role at Brain Resource?

Dr. John Docherty: Sure. The main theme of my work since the 1960s has remained the same, “How do we put knowl­edge into effec­tive use to improve men­tal health?” Over the last cen­tury, med­i­cine made tremen­dous progress in gen­er­at­ing sci­en­tific and clin­i­cal knowl­edge. Basic research dis­cov­ery sci­ence and clin­i­cal treat­ment devel­op­ment sci­ence have made great progress. Within Psy­chi­a­try there was stan­dard set­ting advance in the 1960’s through the NIMH-VA coop­er­a­tive stud­ies to the method­ol­ogy of assess­ing the effi­cacy of psy­chophar­ma­co­log­i­cal drugs. This work estab­lished prin­ci­ples adopted for the study of med­ica­tions in the other areas of med­i­cine. The study of psy­chother­apy, how­ever, lagged in devel­op­ment. In my role of Chief of the Psy­choso­cial Treat­ments Branch of the NIMH , I helped con­tribute to the advance of that work by sup­port­ing the efforts of an extra­or­di­nary group of indi­vid­u­als led by Irene Waskow who car­ried out the TDCRP. This study estab­lished the method­olo­gies that made pos­si­ble the effec­tive sci­en­tific study of the effi­cacy of psy­chother­a­pies. The evi­dence base and of such treat­ments as CBT, DBT, Moti­va­tional Enhance­ment Treat­ment and other evidence-based psy­chother­a­pies derives directly from this study and its sem­i­nal influ­ence. This was a con­tri­bu­tion to the sci­ence of Clin­i­cal Treat­ment Devel­op­ment research.

I would say that my major inter­est, how­ever, has been in the next step, the sci­ence of knowl­edge trans­fer. There has been and remains a long and costly (in terms par­tic­u­larly of unnec­es­sary suf­fer­ing) lag between the devel­op­ment of new knowl­edge and its com­mon and effec­tive use in practice.

In order the help the field moved for­ward, I have worked for the last 20 years in the devel­op­ment and imple­men­ta­tion of meth­ods to effec­tively trans­fer knowl­edge into prac­tice. Read the rest of this entry »

Dr. Michael Merzenich, Emer­i­tus Pro­fes­sor at UCSF, is a lead­ing pio­neer in brain plas­tic­ity research. In the late 1980s, Dr. Merzenich was on the team that invented the cochlear implant. In 1996, he was the found­ing CEO of Sci­en­tific Learn­ing Cor­po­ra­tion (Nas­daq: SCIL), and in 2004 became co-founder and Chief Sci­en­tific Offi­cer of Posit Sci­ence. He was elected to the National Acad­emy of Sci­ences in 1999 and to the Insti­tute of Med­i­cine this year. He retired as Fran­cis A. Sooy Pro­fes­sor and Co-Director of the Keck Cen­ter for Inte­gra­tive Neu­ro­science at the Uni­ver­sity of Cal­i­for­nia at San Fran­cisco in 2007. You may have learned about his work in one of PBS TV spe­cials, mul­ti­ple media appear­ances, or neuroplasticity-related books.

(Alvaro Fer­nan­dez) Dear Michael, thank you very much for agree­ing to par­tic­i­pate in the inau­gural Sharp­Brains Sum­mit in Jan­u­ary, and for your time today. In order to con­tex­tu­al­ize the Summit’s main themes, I would like to focus this inter­view on the likely big-picture impli­ca­tions dur­ing the next 5 years of your work and that of other neu­ro­plas­tic­ity research and indus­try pioneers.

Thank you for invit­ing me. I believe the Sharp­Brains Sum­mit will be very use­ful and stim­u­lat­ing, you are gath­er­ing an impres­sive group together. I am look­ing for­ward to January.

Neuroplasticity-based Tools: The New Health & Well­ness Frontier

There are many dif­fer­ent technology-free approaches to har­ness­ing –enabling, dri­ving– neu­ro­plas­tic­ity. What is the unique value that tech­nol­ogy brings to the cog­ni­tive health table?

It’s all about effi­ciency, scal­a­bil­ity, per­son­al­iza­tion, and assured effec­tive­ness. Tech­nol­ogy sup­ports the imple­men­ta­tion of near-optimally-efficient brain-training strate­gies. Through the Inter­net, it enables the low-cost dis­tri­b­u­tion of these new tools, any­where out in the world. Tech­nol­ogy also enables the per­son­al­iza­tion of brain health train­ing, by pro­vid­ing sim­ple ways to mea­sure and address indi­vid­ual needs in each person’s brain-health train­ing expe­ri­ence. It enables assess­ments of your abil­i­ties that can affirm that your own brain health issues have been effec­tively addressed.

Of course sub­stan­tial gains could also be achieved by orga­niz­ing your every­day activ­i­ties that grow your neu­ro­log­i­cal abil­i­ties and sus­tain your brain health. Still, if the ordi­nary cit­i­zen is to have any real chance of main­tain­ing their brain fit­ness, they’re going to have to spend con­sid­er­able time at the brain gym!

One espe­cially impor­tant con­tri­bu­tion of tech­nol­ogy is the scal­a­bil­ity that it pro­vides for deliv­er­ing brain fit­ness help out into the world. Think about how effi­cient the drug deliv­ery sys­tem is today. Doc­tors pre­scribe drugs, insur­ance cov­ers them, and there is a drug store in every neigh­bor­hood in almost every city in the world so that every patient has access to them. Once neuroplasticity-based tools and out­comes and stan­dard­ized, we can envi­sion a sim­i­lar sce­nario. And we don’t need all those drug stores, because we have the Internet!

Hav­ing said this, there are obvi­ous obsta­cles. One main one, in my mind, is the lack of under­stand­ing of what these new tools can do. Cog­ni­tive train­ing pro­grams, for exam­ple, seem counter-intuitive to con­sumers and many pro­fes­sion­als “ why would one try to improve speed-of-processing if all one cares about is œmem­ory? A sec­ond obvi­ous prob­lem is to get indi­vid­u­als to buy into the effort required to really change their brains for the bet­ter. That buy-in has been achieved for many indi­vid­u­als as it applies to their phys­i­cal health, but we haven’t got­ten that far yet in edu­cat­ing the aver­age older per­son that brain fit­ness train­ing is an equally effort­ful business!

Tools for Safer Dri­ving: Teens and Adults

Safe dri­ving seems to be one area where the ben­e­fits are more intu­itive, which may explain the sig­nif­i­cant traction.

Yes, we see great poten­tial and inter­est among insur­ers for improv­ing dri­ving safety, both for seniors and teens. Appro­pri­ate cog­ni­tive train­ing can lower at-fault acci­dent rates. You can mea­sure clear ben­e­fits in rel­a­tively short time frames, so it won’t take long for insur­ers to see an eco­nomic ratio­nale to not only offer pro­grams at low cost or for free but to incen­tivize dri­vers to com­plete them. All­state, AAA, State Farm and other insur­ers are begin­ning to real­ize this poten­tial. It is impor­tant to note that typ­i­cal acci­dents among teens and seniors are dif­fer­ent, so that train­ing method­olo­gies will need to be dif­fer­ent for dif­fer­ent high-risk populations.

Yet, most dri­ving safety ini­tia­tives today still focus on edu­cat­ing dri­vers, rather that train­ing them neu­ro­log­i­cally. We mea­sure vision, for exam­ple, but com­pletely ignore atten­tional con­trol abil­i­ties, or a driver’s use­ful field of view. I expect this to change sig­nif­i­cantly over the next few years.

Long-term care and health insur­ance com­pa­nies will ulti­mately see sim­i­lar ben­e­fits, and we believe that they will fol­low a sim­i­lar course of action to reduce gen­eral med­ical and neu­rode­gen­er­a­tive dis­ease– (Mild Cog­ni­tive Impair­ment and Alzheimer’s– and Parkinsons-) related costs. In fact, many senior liv­ing com­mu­ni­ties are among the pio­neers in this field.

Boomers & Beyond: Main­tain­ing Cog­ni­tive Vitality

Main­stream media is cov­er­ing this emerg­ing cat­e­gory with thou­sands of sto­ries. But most cov­er­age seems still focused on does it work? more than “how do we define It”, what does work mean? or work for whom, and for what? Can you sum­ma­rize what recent research suggests?

We have seen clear pat­terns in the appli­ca­tion of our train­ing pro­grams, some pub­lished (like IMPACT), some unpub­lished, some with healthy adults, and some with peo­ple with mild cog­ni­tive impair­ment or early Alzheimers Dis­ease (AD). What we see in every case: Read the rest of this entry »

You can see speak­ers and agenda by click­ing on Sharp­Brains Sum­mit. Please reg­is­ter if you are inter­ested in par­tic­i­pat­ing: Jan­u­ary 18-20th 2010 (Pacific Time).

• Con­fer­ence: Jan­u­ary 18-19th. 9–10 pan­els to dis­cuss Mar­ket and Research Insights,  together with online discussions.
• Expo Day: Jan­u­ary 20th. Prod­uct demos by Sponsors.

Con­firmed speak­ers and themes:

Mon­day, Jan­u­ary 18th, 2010:

Cog­ni­tion and Neu­ro­plas­tic­ity: The New Health­care Frontier

• Alvaro Fer­nan­dez, CEO, SharpBrains
• David White­house, Chief Med­ical Offi­cer, OptumHealth Behav­ioral Solutions
• William Reich­man, Pres­i­dent, Baycrest
• P Murali Doraiswamy, Bio­log­i­cal Psy­chi­a­try Divi­sion Head, Duke University

Tools for Safer Dri­ving: Teenagers and Older Adults

• Steven Aldrich, CEO, Posit Science
• Peter Chris­tian­son, Pres­i­dent of Young Dri­vers of Canada
• Jerri Edwards, Assoc. Pro­fes­sor Uni­ver­sity of South Florida

Clin­i­cal Appli­ca­tions: Research­ing, Iden­ti­fy­ing, Treat­ing Cog­ni­tive Deficits

• Keith Wesnes, Prac­tice Leader, United BioSource Corporation
• Jonas Jendi, CEO, Cogmed
• Michel Noir, Pres­i­dent, Sci­en­tific Brain Training
• Elkhonon Gold­berg, Chief Sci­en­tific Advi­sor, SharpBrains

Read the rest of this entry »

(Editor’s Note: given the grow­ing media atten­tion to three appar­ently sep­a­rate worlds –cog­ni­tive enhance­ment via drugs, brain fit­ness train­ing soft­ware, com­put­er­ized neu­rocog­ni­tive assessments-, I found it refresh­ing to see our co-founder Elkhonon Gold­berg intro­duce the topic of cog­notropic drugs with an inte­gra­tive per­spec­tive in the much updated new edi­tion of his clas­sic book, now titled The New Exec­u­tive Brain: Frontal Lobes In A Com­plex World. Below goes an excerpt).

For many neu­ropsy­chol­o­gists, like myself, sci­ence is a labor of love, but see­ing patients is bread and but­ter. Tra­di­tion­ally, the clin­i­cal con­tri­bu­tion of neu­ropsy­chol­ogy has been mostly diag­nos­tic, with pre­cious lit­tle to offer patients by way of treat­ment. Neu­ropsy­chol­ogy is not the only clin­i­cal dis­ci­pline for years con­signed to help­less voyeurism. Every dis­ci­pline con­cerned with cog­ni­tion shares this hum­bling predica­ment. A psy­chi­a­trist treat­ing a schiz­o­phrenic patient or a depressed patient finds him– or her­self in a sim­i­lar posi­tion. There are ample phar­ma­co­log­i­cal tools to treat the patient’s psy­chosis or mood, but very few to treat the patient’s cog­ni­tion. Even though psy­chi­a­trists increas­ingly rec­og­nize that cog­ni­tive impair­ment is often more debil­i­tat­ing in their patients than psy­chosis or mood dis­or­der, tra­di­tion­ally, very lit­tle direct effort has been aimed at improv­ing cognition.

A neu­rol­o­gist treat­ing a patient recov­er­ing from the effects of head injury does not fare much bet­ter. There are ade­quate means to con­trol the patient’s seizures but not his or her cog­ni­tive changes, despite the fact that cog­ni­tive impair­ment is usu­ally far more debil­i­tat­ing than an occa­sional seizure. Soci­ety has been so pre­oc­cu­pied with sav­ing lives, treat­ing hal­lu­ci­na­tions, con­trol­ling seizures, and lift­ing depres­sion that cog­ni­tion (mem­ory, atten­tion, plan­ning, prob­lem solv­ing) has been largely ignored. Granted, var­i­ous neu­rolep­tics, anti­con­vul­sants, anti­de­pres­sants, seda­tives, and stim­u­lants do have an effect on cog­ni­tion, but it is an ancil­lary effect of a drug designed to treat some­thing else.

Alzheimer’s dis­ease and other demen­tias have been society’s wake-up call. Here, in the most afflu­ent coun­try in the most afflu­ent of times, human minds were suc­cumb­ing to decay before human bod­ies, a sharp chal­lenge to the tacit pop­u­lar belief that the “body is frail but soul is for­ever.” This pro­vided an impe­tus for the devel­op­ment of an entirely new class of drugs, which can be termed famil­ially as “cog­notropic.” Their pri­mary and explicit pur­pose is to improve cognition.

Since med­ical and pub­lic pre­oc­cu­pa­tion with demen­tia focuses on mem­ory, most of the phar­ma­co­log­i­cal efforts have been directed at improv­ing mem­ory. At the time of this writ­ing, a hand­ful of drugs known as “Alzheimer’s drugs” or “mem­ory enhancers” have been approved by the U.S. Food and Drug Admin­is­tra­tion (FDA). In real­ity, both des­ig­na­tions are some­what mis­lead­ing. The drugs in ques­tion are Read the rest of this entry »

(Editor’s note: this arti­cle belongs to the excel­lent May 2009 spe­cial issue on Aug­ment­ing Cog­ni­tion of sci­en­tific jour­nal Fron­tiers in Neu­ro­science, Vol­ume 3, Issue 1. You can order this issue, for 50 euros, here. Highly rec­om­mended for sci­en­tists and tech­ni­cal read­ers inter­ested in the sci­ence. This arti­cle, an indus­try overview, is repro­duced here with autho­riza­tion by the Fron­tiers Research Foun­da­tion).

Prepar­ing Soci­ety for the Cog­ni­tive Age

- By Alvaro Fernandez

Ground­break­ing cog­ni­tive neu­ro­science research has occurred over the last 20 years — with­out par­al­lel growth of con­sumer aware­ness and appro­pri­ate pro­fes­sional dis­sem­i­na­tion. “Cog­ni­tion” remains an elu­sive con­cept with unclear impli­ca­tions out­side the research community.

Ear­lier this year, I pre­sented a talk to health care pro­fes­sion­als at the New York Acad­emy of Med­i­cine, titled “Brain Fit­ness Soft­ware: Help­ing Con­sumers Sep­a­rate Hope from Hype”. I explained what com­put­er­ized cog­ni­tive assess­ment and train­ing tools can do (assess/enhance spe­cific cog­ni­tive func­tions), what they can­not do (reduce one’s “brain age”) and the cur­rent uncer­tain­ties about what they can do (i.e., delay Alzheimer’s symp­toms). At the same sym­po­sium, Dr. Gary Kennedy, Direc­tor of Geri­atric Psy­chi­a­try at Mon­te­fiore Med­ical Cen­ter, pro­vided guid­ance on why and how to screen for exec­u­tive func­tion deficits in the con­text of dementia.

I could per­ceive two emerg­ing trends at the event: 1) “Aug­ment­ing Cog­ni­tion” research is most com­monly framed as a health­care, often phar­ma­co­log­i­cal topic, with the tra­di­tional cog­ni­tive bias in med­i­cine of focus­ing on detec­tion and treat­ment of dis­ease, 2) In addi­tion, there is a grow­ing inter­est in non-invasive enhance­ment options and over­all lifestyle issues. Research find­ings in Aug­ment­ing Cog­ni­tion are only just begin­ning to reach the main­stream mar­ket­place, mostly through health­care chan­nels. The oppor­tu­nity is immense, but we will need to ensure the mar­ket­place matures in a ratio­nal and sus­tain­able man­ner, both through health­care and non-healthcare channels.

In Jan­u­ary 2009, we polled the 21,000 sub­scribers of Sharp­Brains’ mar­ket research eNewslet­ter to iden­tify atti­tudes and behav­iors towards the “brain fit­ness” field (a term we chose in 2006 based on a num­ber of con­sumer sur­veys and focus groups to con­nect with a wider audi­ence). Over 2,000 decision-makers and early adopters responded to the survey.

One of the key ques­tions we asked was, “What is the most impor­tant prob­lem you see in the brain fit­ness field and how do you think it can be solved?”. Some exam­ples of the sur­vey free text answers are quoted here, together with my suggestions.

Most impor­tant prob­lems in the brain fit­ness field

Pub­lic aware­ness (39%): “To get peo­ple to under­stand that hered­ity alone does not decide brain func­tion­ing”. We need to ramp up efforts to build pub­lic aware­ness and enthu­si­asm about brain research, includ­ing estab­lish­ing clear links to daily liv­ing. We can col­lab­o­rate with ini­tia­tives such as the Dana Foundation’s Brain Aware­ness Week and use the recent “Neu­ro­science Core Con­cepts” mate­ri­als devel­oped by the Soci­ety for Neu­ro­science to give talks at schools, libraries and workplaces.

Claims (21%): “The lack of stan­dards and clear def­i­n­i­tions is very con­fus­ing, and Read the rest of this entry »

The Longevity Div­i­dend is a the­ory that says we hope to inter­vene sci­en­tif­i­cally to slow the aging process, which will also delay the onset of age-related dis­eases. Delay­ing aging just seven years would slash rates of con­di­tions like can­cer, dia­betes, Alzheimer’s dis­ease and heart dis­ease in half. That’s the longevity part.

The div­i­dend comes from the social, eco­nomic, and health bonuses that would then be avail­able to spend on schools, energy, jobs, infra­struc­ture tril­lions of dol­lars that today we spend on health­care ser­vices. In fact, at the rate we’re going, by the year 2020 one out of every $5 spent in this coun­try will be spent on health­care. Obvi­ously, some­thing has to change.

Enter the Longevity Div­i­dend. The Longevity Div­i­dend doesn’t sug­gest that we live longer; instead, it calls for liv­ing bet­ter. The idea is that if we use sci­ence to increase healthspan, not lifes­pan. In other words, tomor­rows 50-year-old would have the health pro­file of a 43-year-old.

It might sound like sci­ence fic­tion, but, in fact, it’s quite pos­si­ble. We’re already doing it in some ani­mal mod­els using genetic and dietary inter­ven­tions, tech­niques related to what sci­en­tists call “the biol­ogy of aging.”

Get­ting there in humans, how­ever, means embrac­ing an entirely new approach to our think­ing about dis­ease and aging, and how we con­duct sci­en­tific research into the two.

Get­ting Sci­en­tists’ Attention

A group of emi­nent researchers first pro­posed the Longevity Div­i­dend in a 2006 arti­cle pub­lished in The Sci­en­tist. The authors, S. Jay Olshan­sky, PhD, pro­fes­sor of epi­demi­ol­ogy and bio­sta­t­ics at the Uni­ver­sity of Illi­nois in Chicago, Daniel P. Perry, exec­u­tive direc­tor of the Alliance for Aging Research in Wash­ing­ton, DC, Richard A. Miller, MD, PhD, pro­fes­sor of pathol­ogy at the Uni­ver­sity of Michi­gan in Ann Arbor, and Robert N. But­ler, MD, pres­i­dent and CEO of the Inter­na­tional Longevity Cen­ter in New York, intended their essay to be a “gen­eral state­ment to sci­en­tists about the need for a par­a­digm shift in the way we think about aging and disease.

The researchers also met with U.S. sen­a­tors who served on the Sen­ate com­mit­tee that over­saw the bud­get for the National Insti­tutes of Health (NIH). “We told them we believed Read the rest of this entry »

Hiroshi Komiyama, Pres­i­dent of the Uni­ver­sity of Tokyo and Chair­per­son of the Global Agenda Coun­cil on the Chal­lenges of Geron­tol­ogy I am a mem­ber of, just pro­vided coun­cil mem­bers with a brief update of his par­tic­i­pa­tion in the recent World Eco­nomic Forum.

Part of the pro­ceed­ings are pub­lic — you may enjoy read­ing this panel write-up of the ses­sion Health­care under Stress:

- “Japan has the world’s old­est pop­u­la­tion. Health and longevity cre­ate wealth and, thus, “health begets wealth”. It is doc­u­mented that nations that develop a five-year life expectancy advan­tage also cre­ate a larger GDP. A healthy child­hood and adult­hood con­tribute to a more pro­duc­tive old age. New mar­kets and indus­tries are aris­ing – “sil­ver indus­tries” such as finan­cial ser­vices, health, hous­ing and hos­pi­tal­ity geared to senior cit­i­zens. Longevity needs to be linked to health – includ­ing cog­ni­tive health – and lifestyle choices play a major role in health.”

- “The pub­lic health focus is shift­ing from infec­tions to car­dio­vas­cu­lar dis­eases. Com­plex new mod­els are nec­es­sary to develop bet­ter responses and improved health – with the pri­mary empha­sis on “really good pri­mary health­care” and pre­ven­tion – to lower costs. Pre­ven­tion increases the healthy years of a person’s life. The chal­lenge is cre­at­ing the incen­tive for pre­ven­tion: how can peo­ple be encour­aged to make healthy choices? Mobi­lized pop­u­la­tions can drive the change. Fin­land has an 80% lower inci­dence of heart dis­ease than 30 years ago due to such incentives.”

Full write-up: Health­care under Stress

Related arti­cles:

- The Future of the Aging Soci­ety: Bur­den or Human Capital?

- Update: Global Con­sor­tium for Neu­rocog­ni­tive Fit­ness Innovation